Pharmacia Plans Camptosar Submission For Labeling Change By Year-End
Executive Summary
Pharmacia will submit a labeling change proposal for its colorectal cancer therapy Camptosar by the end of the year based on FDA's Oncologic Drugs Advisory Committee Dec. 6 review of postmarketing safety
You may also be interested in...
Camptosar Label Revision Strengthens Monitoring Of Patients With Diarrhea
Pharmacia Camptosar revised labeling strengthens recommendations on monitoring patients with diarrhea
Camptosar Label Revision Strengthens Monitoring Of Patients With Diarrhea
Pharmacia Camptosar revised labeling strengthens recommendations on monitoring patients with diarrhea
Pharmacia Expects Camptosar Sales To Rebound As Safety Concerns Resolve
Pharmacia expects sales of its colorectal cancer therapy Camptosar to rebound following a positive review of postmarketing safety data by FDA's Oncologic Drugs Advisory Committee